These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 15490382)

  • 1. Managing metastatic bone disease: three case studies.
    Coleman R; Heidenreich A; Bell R
    Semin Oncol; 2004 Oct; 31(5 Suppl 10):83-6. PubMed ID: 15490382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ibandronate in metastatic bone pain.
    Heidenreich A; Ohlmann C; Body JJ
    Semin Oncol; 2004 Oct; 31(5 Suppl 10):67-72. PubMed ID: 15490379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ibandronate reduces skeletal morbidity in patients with breast cancer.
    Tripathy A D; Diel I; Body JJ
    Semin Oncol; 2004 Oct; 31(5 Suppl 10):64-6. PubMed ID: 15490378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Double-blind, randomised, placebo-controlled, dose-finding study of oral ibandronate in patients with metastatic bone disease.
    Coleman RE; Purohit OP; Black C; Vinholes JJ; Schlosser K; Huss H; Quinn KJ; Kanis J
    Ann Oncol; 1999 Mar; 10(3):311-6. PubMed ID: 10355575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bone pain reduction in patients with metastatic breast cancer treated with ibandronate-results from a post-marketing surveillance study.
    Diel IJ; Kurth AH; Sittig HB; Meden H; Maasberg M; Sandermann A; Bergner R
    Support Care Cancer; 2010 Oct; 18(10):1305-12. PubMed ID: 20151162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies.
    Body JJ; Diel IJ; Lichinitzer M; Lazarev A; Pecherstorfer M; Bell R; Tripathy D; Bergstrom B
    Br J Cancer; 2004 Mar; 90(6):1133-7. PubMed ID: 15026791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review of ibandronate in the treatment of metastatic bone disease: experience from phase III trials.
    Tripathy D; Body JJ; Bergström B
    Clin Ther; 2004 Dec; 26(12):1947-59. PubMed ID: 15823760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomized, double-blind, placebo-controlled trial.
    Tripathy D; Lichinitzer M; Lazarev A; MacLachlan SA; Apffelstaedt J; Budde M; Bergstrom B;
    Ann Oncol; 2004 May; 15(5):743-50. PubMed ID: 15111341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient management issues in metastatic bone disease.
    Cameron D
    Semin Oncol; 2004 Oct; 31(5 Suppl 10):79-82. PubMed ID: 15490381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of ibandronate in the treatment of neoplastic bone disease.
    Pecherstorfer M
    Expert Opin Pharmacother; 2004 Nov; 5(11):2341-50. PubMed ID: 15500381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bisphosphonates for breast cancer.
    Pavlakis N; Stockler M
    Cochrane Database Syst Rev; 2002; (1):CD003474. PubMed ID: 11869664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ibandronate: its role in metastatic breast cancer.
    Cameron D; Fallon M; Diel I
    Oncologist; 2006; 11 Suppl 1():27-33. PubMed ID: 16971737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of oral ibandronate versus IV zoledronic acid or IV pamidronate for bone metastases in patients receiving oral hormonal therapy for breast cancer in the United Kingdom.
    De Cock E; Hutton J; Canney P; Body JJ; Barrett-Lee P; Neary MP; Lewis G
    Clin Ther; 2005 Aug; 27(8):1295-310. PubMed ID: 16199254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases.
    Body JJ; Diel IJ; Lichinitser MR; Kreuser ED; Dornoff W; Gorbunova VA; Budde M; Bergström B;
    Ann Oncol; 2003 Sep; 14(9):1399-405. PubMed ID: 12954579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of oral ibandronate compared with intravenous (i.v.) zoledronic acid or i.v. generic pamidronate in breast cancer patients with metastatic bone disease undergoing i.v. chemotherapy.
    De Cock E; Hutton J; Canney P; Body JJ; Barrett-Lee P; Neary MP; Lewis G
    Support Care Cancer; 2005 Dec; 13(12):975-86. PubMed ID: 15871033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bisphosphonates and reduction of skeletal events in patients with bone metastatic breast cancer.
    Rizzoli R
    Ann Oncol; 2004 May; 15(5):700-1. PubMed ID: 15111335
    [No Abstract]   [Full Text] [Related]  

  • 17. Safety of intravenous and oral bisphosphonates and compliance with dosing regimens.
    Conte P; Guarneri V
    Oncologist; 2004; 9 Suppl 4():28-37. PubMed ID: 15459427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid administration of ibandronate does not affect renal functioning: evidence from clinical studies in metastatic bone disease and hypercalcaemia of malignancy.
    Pecherstorfer M; Diel IJ
    Support Care Cancer; 2004 Dec; 12(12):877-81. PubMed ID: 15372222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer.
    Diel IJ; Body JJ; Lichinitser MR; Kreuser ED; Dornoff W; Gorbunova VA; Budde M; Bergström B;
    Eur J Cancer; 2004 Jul; 40(11):1704-12. PubMed ID: 15251160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The role of ibandronate in the daily oncological practice].
    Nagykálnai T
    Magy Onkol; 2006; 50(4):325-7. PubMed ID: 17216006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.